Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $290.28M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.90M
Average 0.38M
EVMN EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Evommune, Inc.NYSE: EVMN
EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026
EPS (Diluted) remains negative
Q1 FY2026 EPS (Diluted) was -$0.64, compared with -$0.48 a year earlier. Trailing-twelve-month EPS (Diluted) was -$2.39.
Context
- EPS (Diluted) grew in size in 1 of the last 2 fiscal years.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 8 analysts of -$3.32 (-52.3%) for the fiscal year ending Dec 2026, a slowdown from the +4.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.64+28.9% QoQ
- Last fiscal yearDec 2025
- -$2.18+4.0% YoY
- LTMMar 2026
- -$2.39— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -33.3% | -47.7% | -14.3 pp |
| 1 year | +4.0% | -52.3% | -56.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (2.18) USD
- Year-over-year change
- +4.0%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.18) | +4.0% |
| FY2024 | 2024-12-31 | (2.27) | -100.9% |
| FY2023 | 2023-12-31 | (1.13) | — |
EPS (Diluted) vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's LTM Mar 2026 EPS (Diluted) of -$2.39 is the 7th highest of the 10 companies compared; the peer median is -$0.78.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $9.35 | +333.8% | — | |
| LTM Sep 2026 | $0.52 | +161.9% | — | |
| LTM Mar 2026 | -$0.37 | +63.0% | — | |
| LTM Mar 2026 | -$0.46 | +20.7% | — | |
CLYMClimb Bio, Inc. | LTM Mar 2026 | -$0.78 | +67.2% | — |
FTREFortrea Holdings Inc. | LTM Jun 2026 | -$0.93 | +91.9% | — |
EVMNEvommune, Inc. | LTM Mar 2026 | -$2.39 | — | — |
| LTM Mar 2026 | -$3.5 | -45.2% | — | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | -$3.55 | -11.3% | — |
| LTM Mar 2026 | -$15.07 | -13.7% | — | |
| Peer median (excluding EVMN) | -$0.78 | +63.0% | — | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 5M | 7M | 13M |
| Cost of Revenue | 1M | 1.29M | 0 |
| Gross Profit | 4M | 5.71M | 13M |
| Gross Margin | 80.0% | 81.6% | 100.0% |
| Research & Development | 32M | 64.24M | 74.04M |
| Selling, General & Admin | 9.85M | 11.48M | 20.03M |
| Operating Expenses | 41.85M | 75.73M | 94.07M |
| Depreciation & Amortization | 1M | 1.29M | 1.39M |
| EBITDA | (33M) | (65.49M) | (67.48M) |
| EBITDA Margin | -659.9% | -935.5% | -519.1% |
| Operating Income | (37.85M) | (70.01M) | (81.07M) |
| Operating Margin | -757.0% | -1000.2% | -623.6% |
| Interest Income | 3.86M | 3.24M | 3.32M |
| Interest Expense | 58K | 34K | 0 |
| Other Income / Expenses | 3.8M | 3.2M | 12.2M |
| Income Before Tax | (34.05M) | (66.81M) | (68.87M) |
| Pre-Tax Margin | -681.1% | -954.4% | -529.8% |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (34.05M) | (66.81M) | (68.87M) |
| Net Margin | -681.1% | -954.4% | -529.8% |
| EPS (Basic) | (1.13) | (2.27) | (2.18) |
| EPS (Diluted) | (1.13) | (2.27) | (2.18) |
| Weighted Avg Shares | 30.08M | 30.08M | 31.52M |
| Weighted Avg Shares (Diluted) | 30.08M | 30.08M | 31.52M |
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$7.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.